NL
DE
27 August 2020
Led by Satish Lubeek of the Department of Dermatology (photo), physician-researchers Marieke van Winden and Lara van der Schoot - together with other researchers - have conducted research into the effectiveness and safety of systemic anti-psoriasis therapies in patients over 65 years of age.
More research from daily practice, as well as (sub)analyses of prospective cohort studies on the effectiveness and safety of systemic therapies in older adults, are crucial for optimizing personalized, effective and safe anti-psoriasis treatments in this growing patient group.
The research was recently published in the scientific medical journal Journal of the American Medical Association: Jama Dermatology. It is also discussed in the corresponding editorial.
Led by Satish Lubeek of the Department of Dermatology (photo), physician-researchers Marieke van Winden and Lara van der Schoot - together with other researchers - have conducted research into the effectiveness and safety of systemic anti-psoriasis therapies in patients over 65 years of age.
Findings
It seems that the effectiveness of treatment with acitretin, etanercept, adalimumab and secukinumab is not affected by advanced age. Studies of other systemic anti-psoriasis drugs have not made age group comparisons. Older age was significantly associated with impairment of renal function in users of ciclosporin and lymphopenia in users of fumaric acid. Infections were the most frequently reported side effect in patients over 65 years of age using biologics; no significant association with age was found.Conclusions and relevance
Based on the very limited relevant studies available, age alone should not be a limiting factor in the treatment of psoriasis. Awareness of other medical conditions and concomitant medication use is very important in older adults, as well as possible dosage adjustments and frequent laboratory and clinical monitoring.More research from daily practice, as well as (sub)analyses of prospective cohort studies on the effectiveness and safety of systemic therapies in older adults, are crucial for optimizing personalized, effective and safe anti-psoriasis treatments in this growing patient group.
The research was recently published in the scientific medical journal Journal of the American Medical Association: Jama Dermatology. It is also discussed in the corresponding editorial.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Large NWA ORC grant awarded for national skin research: Next Generation ImmunoDermatology
23 March 2022Research for better treatment methods for chronic skin diseases.
read more
ZonMw funding for PSIDER program
14 July 2021Michiel Vermeulen, Klaas Mulder and Nael Nadif Kasri receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis.
read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy
15 April 2021 The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period. read more
Tight controlled dose reduction of biologics in psoriasis patients
7 May 2020 Published in JAMA Dermatology, RIHS researcher Selma Atalay and colleagues investigated in a randomized controlled trial a tight controlled dose reduction strategy of the biologics adalimumab, etanercept and ustekinumab in psoriasis patients. read more
Guiding the surgeon real-time tumor visualization during surgery
26 February 2020 Incomplete excision of tumor tissue negatively affects the prognosis of the patient. RIHS researcher Mark Rijpkema and colleagues are working on the development of new dual-labeled tracers and currently are implementing this into the clinic. read more
